A high-tech form of radiotherapy that shapes radiation beams to tumours can dramatically improve outcomes for patients with prostate cancer, long-term clinical trial results show.
Institute of Cancer Research
Radiotherapy following mastectomy for intermediate-stage, high-risk breast cancer can be shortened from five to three weeks while maintaining tumour control rates in the breast and surrounding region that are equivalent to conventional treatment.
A higher-dose, shorter form of radiation is safe, effective, and no more damaging to the breast tissue or skin of breast cancer patients under age 50 than it is in older patients.
A new survey finds breast cancer patients’ actual radiotherapy experiences largely exceeded their expectations.
Researchers have found that a 50 percent reduction in the intensity and dose of radiation therapy for patients with HPV-related throat cancer reduced side effects with no loss in survival and no decrease in cure rates.
Tumour treating fields are safe and efficacious when used with temozolomide for glioblastoma treatment, according to a late-breaking abstract presented at the 2017 American Society for Radiation Oncology (ASTRO) Annual Meeting.
Cancer Therapy Advisor
Shrink accelerators, sharpen beams and broaden health-care coverage so more people can get this type of radiotherapy treatment.
Action Radiotherapy will regularly update our jobs page on our website. For up to date band 5, 6, 7 and band 8+ jobs, please click on the following link.
Combining radiotherapy with chemotherapy for patients with limited metastatic non-small cell lung cancer (NSCLC) may curb disease progression dramatically when compared to NSCLC patients who only receive chemotherapy, according to a new randomised phase II clinical trial reported today at the 59th Annual Meeting of the American Society for Radiation Oncology (ASTRO).
Long-term results of a phase III clinical trial indicate that survival rates for patients receiving chemo-radiotherapy for un-resectable, locally advanced non-small cell lung cancer may be more than twice as high as previous estimates. Findings will be presented at the 59th Annual Meeting of the American Society for Radiation Oncology (ASTRO) in San Diego.